Abbott Laboratories (ABT)

[DewDiligence]

(ABT)—EXAS Cologuard patents ruled invalid, paving the way for competition:

https://www.businesswire.com/news/home/20260206045746/en/Geneoscopy-Wins-Second-Patent-Trial-and-Appeal-Board-Decision-Invalidating-All-Challenged-Claims-of-Exact-Sciences-746-Patent

Geneoscopy, a private company, has a Cologuard-like test called ColoSense that has not yet been commercialized due to patent litigation by EXAS. With the above ruling by the PTAB, Geneoscopy can now proceed with commercialization.

I do not have an educated opinion on which test is better from a medical standpoint.

ABT, which is buying EXAS in an all-cash deal (#msg- 176971675), is down 0.2% in today’s AH session, so ABT investors evidently think Cologuard competition from ColoSense is not a big deal.